Huntington's treatment quest reaches first pluripotent stem cell trial, with safety now under review. An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented at the ISSCR 2026 Annual Meeting.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented at the ISSCR 2026 Annual Meeting. The Phase Ib/IIa REGEN4HD study represents a significant translational milestone following years of preclinical research, pivotal safety studies, regulatory engagement and clinical trial development.
- Ponto de atenção: huntington.
- Ponto de atenção: treatment.
- Ponto de atenção: quest.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/d179474a-2f12-4be1-826d-b37e5bd62bd9.png)